dd1

DD1 (HUN85111) is a proteasome inhibitor that induces human myeloid tumor-selective apoptosis.

DDD100097 is a potent N-myristoyltransferase inhibitor with potential inhibitory effects on Trypanosoma brucei, which can be used to study neurological disorders.

FSDD1I, an albumin-binding fibroblast activation protein (FAP) ligand, can be tagged with 68 Ga and 177 Lu for use in single photon emission computed tomography (SPECT) imaging [1].

CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].

CDD-1102 HCl is a novel BRDT-BD4 / BRD2-BD1302 selective inhibitor that shows non-hormonal contraceptive potential in ex vivo experiments.

EIDD-1931 (Beta-d-N4-hydroxycytidine) is a ribonucleoside analog with antiviral activity that inhibits the replication of severe acute respiratory syndrome coronavirus [SARS-CoV] in Vero 76 cells, Middle East respiratory syndrome coronavirus [MERS-CoV] in Calu-3 2B4 cells, and SARS-CoV-2 in Vero cells (IC50s = 0.1, 0.15, and 0.3 μM, respectively).

(E)-Alprenoxime, the isomer of Alprenoxime, is a site-activated ocular β-blocker.

CDD-1431 is a highly selective BMPR2 kinase inhibitor with a Kiapp of 20.6 nM. It inhibits BRE reporter gene activity, exhibiting an IC50 of 4.87 μM. BMPs regulate cellular processes across various tissue types such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.

CDD-1281 is a potent and highly selective inhibitor of the BMPR2 kinase, with an IC50 value of 1.2 nM. It effectively blocks BMP-mediated gene expression.

CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.

3-Hydroxyoctanoic Acid-d12 is the deuterated analog of 3-Hydroxyoctanoic Acid.

ADD 17014 is an anticonvulsant agent. It has a broad and unique spectrum of anticonvulsant activity.

EIDD-1619 is a novel water-soluble analog of progesterone.

DD-161515 is a VR1 antagonist.

Irgarol is a highly specific and effective inhibitor of photosynthesis.

CDD-1132 showed high affinity in BD2 DEC-Tec assay with an IC50 value of 13 nM.

CDD-1498 showed weak affinity for BRDT-BD1 with IC50 values >10 μM.

CDD-1154 had an IC50 value of 139 nM in the BD2 DEC-Tec assay.

CDD-1128 in BD2 DEC-Tec assay with an affinity value of 521 nM.

CDD-1349 had an IC50 value of 22 nM in a BD2 DEC-Tec assay.

CDD-1147 had an IC50 value of 94 nM in a BD2 DEC-Tec assay.

CDD-1819, a non-covalent and non-peptide compound, serves as a potent SARS-CoV-2 Mpro inhibitor, exhibiting a K i value of 5 nM. It also effectively inhibits the Mpro variants ΔP168, A173V, and ΔP168/A173V [1].

CDD-1733 is a potent, non-covalent, and non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro) with an inhibition constant (K i) of 12 nM. It effectively inhibits Mpro variants including ΔP168, A173V, and the combined ΔP168/A173V [1].

CDD-1845, a non-covalent, non-peptide inhibitor, exhibits potent inhibition of SARS-CoV-2 M^pro with a K_i value of 3 nM. Additionally, CDD-1845 is effective against M^pro variants ΔP168, A173V, and the combined ΔP168/A173V variant [1].